Results 91 to 100 of about 1,991 (194)

Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy [PDF]

Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable ...
Biagini, Elena, Charron, Philippe, Desai, Milind Y., Elliott, Perry, Fernandes, Fabio, Gonzalez-Lopez, Esther, Haelst, Paul L. van, Haugaa, Kristina Hermann, Kramer, Christopher M., Maurizi, Niccolo, Meder, Benjamin, Michels, Michelle, Owens, Anjali, Yuasa, Shinsuke   +13 more
core   +2 more sources

Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy – an updated Meta-Analysis of randomized controlled trials

International Journal of Cardiology: Heart & Vasculature
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with risk of sudden cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK-461, a myosin inhibitor of cardiac myocytes is studied in symptomatic HCM.
Irfan Ullah, Syeda Tayyaba Rehan, Zayeema Khan, Syed Hasan Shuja, Muhammad Hamza Shuja, Muhammad Irfan, Karthik Gonuguntla, M Chadi Alraies, Pratik Aggarwal, Sameer Raina, Yasar Sattar, Muhammad Sohaib Asghar   +11 more
doaj   +1 more source

A MECHANISTIC STUDY OF SARCOMERE LENGTH-DEPENDENT CALCIUM SENSITIVITY REGULATION OF CARDIAC MYOFILAMENTS [PDF]

Sarcomere length-dependent activation (sLDA) of cardiac filaments describes the maximum force performance and the calcium sensitivity, both of which increase with the sarcomere length during the diastolic state.
Wang, Xutu
core   +2 more sources

Case Report: Transient hypertension and myalgia following mavacamten therapy in a patient with hypertrophic obstructive cardiomyopathy

Frontiers in Cardiovascular Medicine
BackgroundMavacamten has been demonstrated to be effective in the treatment of hypertrophic obstructive cardiomyopathy (HOCM). However, its hemodynamic impact and extracardiac effects require further characterization.Case presentationWe report a case of ...
Mengling Peng, Yu Fu, Cong Qin, Shanshan Zhou, Jian Sun   +4 more
doaj   +1 more source

Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target [PDF]

Introduction: Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disease marked by abnormal ventricular hypertrophy. Recent studies have highlighted that left atrial (LA) remodelling—including dilation, fibrosis, and functional impairment ...
Cameli, Matteo, D'Ascenzi, Flavio, Olivotto, Iacopo, Petrone, Alessio, Piazzai, Chiara, Stefanini, Andrea   +5 more
core   +1 more source

Hypertrophic Cardiomyopathy in Athletes: A Paradigm Shift in Exercise Safety, the Role of Comorbid Factors, and the Impact of Anabolic Steroids - A Literature Review

Quality in Sport
    Hypertrophic cardiomyopathy (HCM) in athletes is a complex condition requiring individualized risk assessment and interdisciplinary management.
Martyna Jakubowska, Paulina Jakubowska, Mikołaj Szaryński, Julia Gólcz, Adam Sikorski, Adrian Gólcz, Karolina Kadłubowska, Jan Rytel, Natalia Chojnowska, Tomasz Bursztyn, Michał Bursztyn   +10 more
doaj   +1 more source

Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre

ESC Heart Failure
Aims In clinical trials, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Zaid Abood, Muhammad Fuad Jan, Muddasir Ashraf, Stacie Kroboth, Heather Sanders, McKenzie Schweitzer, Amanda Misicka, Emily Ollerman, Arshad Jahangir, Patrycja Galazka, Abdul Jamil Tajik   +10 more
doaj   +1 more source

Increasing Cardiac Myosin Super-Relaxation With Decreasing Metabolic Demand [PDF]

I schemic heart disease often leads to heart failure with reduced ejection fraction and to a puzzling condition termed hibernating myocardium, where the left ventricle is dysfunctional but still viable.1 Strikingly, the hibernating myocardium experiences
Galán-Arriola, Carlos, Ibanez, Borja, Ochala, Julien, Veiberg, Vebjørn   +3 more
core   +1 more source

A New Era in the Management of Hypertrophic Cardiomyopathy [PDF]

Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease.
Jimenez-Mendez, Cesar, Lara-Palomo, Ana, Llamas-Gomez, Helena, Palomino-Doza, Julian, Perez-Asensio, Ana, Villar-Ruiz, Alberto   +5 more
core   +2 more sources

Impact of Mavacamten on Force Generation in Single Myofibrils from Rabbit Psoas and Human Cardiac Muscle [PDF]

, 2020
Coppini, Raffaele, Dente, Marica, Ferrantini, Cecilia, Piroddi, Nicoletta, Poggesi, Corrado, Scellini, Beatrice, Tesi, Chiara   +6 more
core   +1 more source